

Future Infectious Disease Nucleic Acid Testing

<https://marketpublishers.com/r/I141C0CA9CDEN.html>

Date: February 2012

Pages: 360

Price: US\$ 2,000.00 (Single User License)

ID: I141C0CA9CDEN

Abstracts

This 360-page report presents an overview of the clinical significance and market needs for major infectious diseases, as well as extensive listings of companies developing and marketing molecular diagnostic technologies and products.

Contains 360 pages and 20 tables

Contents

1. OVERVIEW

2. MAJOR INFECTIOUS DISEASES

AIDS

- Structure and Composition

- Classification

- AIDS Origins

- Animal Lentivirus Systems

- Virus Receptors

- HIV Infections in Humans

 - Pathogenesis and Pathology

- CD4T Lymphocytes and Memory Cells

- Monocytes and Macrophages

- Lymphoid Organs

- Neural Cells

- Viral Coinfections

 - Clinical Findings

- Plasma Viral Load

- Pediatric AIDS

 - Neurologic Disease

 - Opportunistic Infections

 - Cancer

- Immunity

 - Virus Isolation

 - Serology

 - Viral Nucleic Acid/Antigen Detection

- Epidemiology

 - Worldwide Spread of AIDS

 - United States

 - Routes of Transmission

- DNA Probes

 - Overview

 - Quantitative PCR

 - In Situ PCR

 - Needed Improvements

- Viral Load/Drug Resistance Testing

- Genotype and Phenotype Testing
- Blood Banking Considerations
- Adenovirus
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
 - Adeno-Associated Viruses (AAV)
- Anthrax/Bacillus Anthracis
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Babesiosis
 - Background
- BEA and Other Bartonella Diseases
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Chagas Disease
 - Background
- Campylobacter
 - Background
 - Diagnostic Tests
 - Culture Identification
 - Vaccines and Drugs
- Chlamydia
 - Background
 - Chlamydia psittaci
 - Chlamydia pneumoniae
 - Chlamydia trachomatis
 - Diagnostic Tests
 - Vaccines and Drugs
- Creutzfeldt-Jakob's Disease
 - Background
 - Blood Transmission
 - Diagnostic Tests
 - Major Commercial and Academic Players
 - Bayer
 - Disease Sciences/Bio Tec Global
 - Imperial College School of Medicine

- Ortho-Clinical Diagnostics
- Pall
- ProMetic Life Sciences
- Proteome Sciences/Idexx
- Q-One Biotech
- Serono
- U.S. Agricultural Research Service
- Drugs
- Vaccines
- Cytomegalovirus
 - Background
 - Chorioretinitis
 - Gastrointestinal
 - Central Nervous System Disease
 - Diagnostic Tests
 - Vaccines and Drugs
- Ebola Virus
 - Background
 - Epidemiology
 - Clinical Syndromes
 - Diagnostic Tests
 - Vaccines and Drugs
- EchoVirus
 - Background
 - Acute Aseptic Meningitis
 - Encephalitis
 - Exanthems
 - Respiratory Disease
 - Myopericarditis
 - Neonatal Infections
 - Diagnostic Tests
 - Vaccines and Drugs
- Encephalitis
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Enteroviruses
 - Background
 - Diagnostic Tests

- Viral Isolation and Identification
 - Antibody Tests
 - Vaccines and Drugs
- Epstein-Barr Virus
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Gonorrhea
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Hepatitis
 - Hepatitis A
 - Hepatitis B
 - Structure and Composition
 - Replication
 - Hepatitis C
 - Hepatitis D (Delta)
 - Hepatitis E
 - Hepatitis G
 - Hepatitis Infections Pathology
 - Clinical Findings
 - Laboratory Tests
 - Hepatitis A
 - Hepatitis B
 - Hepatitis C
 - Hepatitis D
 - Hepatitis E
 - Virus-Host Immune Reactions
- Epidemiology
 - Hepatitis A
 - Hepatitis B
 - Hepatitis C
 - Hepatitis D (Delta)
 - Vaccines and Drugs
- Herpes Simplex Virus
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs

Legionella

- Background

- Diagnostic Tests

- Vaccines and Drugs

Lyme Disease

- Background

- Clinical Description

- Clinical Case Definition

- Laboratory Criteria for Diagnosis

- Case Classification

- Diagnostic Tests

- Vaccines and Drugs

Malaria

Mycoplasma

- Background

- Ureaplasma Urealyticum & Mycoplasma Hominis

- Diagnostic Tests

- Vaccines and Drugs

Papillomaviruses/HPV

- Background

- HPV in Cancer

- Cervical Neoplasm

- Diagnostic Tests

- Vaccines and Drugs

- Prevention

Parvovirus B19

- Background

- Microbiology

- Epidemiology

- Clinical Syndromes

- Erythema Infectiosum (Slapped Cheek)

- Adult Polyarthropathy

- Transient Aplastic Crisis

- Transient Pancytopenia

- Red Cell Aplasia in Immunocompromised

- Perinatal Infections

- Diagnostic Test

- Vaccines and Drugs

Pneumonia

- Background
- Diagnostic Tests
- Vaccines and Drugs
- Polyomaviruses
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Salmonellosis
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Shigellosis
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Streptococci
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
 - Group A Streptococci
 - Group B Streptococci
- Toxoplasmosis
 - Background
 - Diagnostic Tests
 - Vaccines and Drugs
- Tuberculosis
 - Background
 - Diagnostic Tests
 - Microscopic Characteristics
 - Cultural Characteristics
 - Skin Tests
 - MDRTB
 - Vaccines and Drugs
- West Nile Virus
 - Background
 - Clinical Syndromes
 - Diagnostic Tests
 - Vaccines and Drugs
- Yersinia

Background

Diagnostic Tests

Vaccines and Drugs

3. ANTIBIOTIC SUSCEPTIBILITY

List Of Tables

LIST OF TABLES

Table 1: Major Companies Developing or Marketing AIDS NAT and other Direct Identification Tests

Table 2: Major Companies Developing or Marketing Adenovirus NAT and other Direct Identification Tests

Table 3: Major Companies Developing or Marketing Campylobacter NAT and Other Direct Identification Tests

Table 4: Major Companies Developing or Marketing Chlamydia NAT and other Direct Identification Tests

Table 5: Major Companies Developing or Marketing CMV NAT and other Direct Identification Tests

Table 6: Major Companies Developing or Marketing EBV NAT and other Direct Identification Tests

Table 7: Major Companies Developing or Marketing Gonorrhea NAT and other Direct Identification Tests

Table 8: Major Companies Developing or Marketing Hepatitis NAT and other Direct Identification Tests

Table 9: Major Companies Developing or Marketing Herpes NAT and other Direct Identification Tests

Table 10: Major Companies Developing or Marketing Legionella NAT and other Direct Identification Tests

Table 11: Major Companies Developing or Marketing Lyme Disease NAT And Other Direct Identification Tests

Table 12: Major Companies Developing or Marketing Mycoplasma NAT And other Direct Identification Tests

Table 13: Major Companies Developing or Marketing Papilloma Virus NAT And Other Direct Identification Tests

Table 14: Major Companies Developing or Marketing Pneumonia NAT And other Direct Identification Tests

Table 15: Major Companies Developing or Marketing Salmonella NAT And other Direct Identification Tests

Table 16: Major Companies Developing or Marketing Shigella NAT And other Direct Identification Tests

Table 17: Major Companies Developing or Marketing Streptococci NAT And Other Direct Identification Tests

Table 18: Major Companies Developing or Marketing Toxoplasmosis NAT And Other

Direct Identification Tests

Table 19: Major Companies Developing or Marketing Tuberculosis NAT And Other Direct Identification Tests

I would like to order

Product name: Future Infectious Disease Nucleic Acid Testing

Product link: <https://marketpublishers.com/r/l141C0CA9CDEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l141C0CA9CDEN.html>